tailieunhanh - Ipilimumab and immune-mediated adverse events: A case report of anti-CTLA4 induced ileitis

Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 , a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for the treatment of metastatic melanoma. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN